How to treat skin rash while taking Vemurafenib

Vemurafenib (Vemurafenib) can cause rash, with an overall incidence of 64%-75%, mostly grade 1 or 2. Grade 3 rash is uncommon, affecting 8% of patients. Rashes include many subtypes such as maculopapular, follicular, erythema, capillary keratosis, or other unspecified rashes. Rash usually appears early, with a median time to onset of vemurafenib of 1.6 weeks. The rash affects the face, neck, trunk, and extremities and is accompanied by itching or pain to varying degrees.

The development or severity of the rash does not appear to be related to tumor response, and patients who develop a rash should undergo a physical examination to obtain an accurate assessment. The primary treatment for maculopapular rash begins with topical steroids and oral antihistamines. Refractory cases may require systemic steroids, interruption of vemurafenib therapy, and referral to a dermatologist. For follicular hyperkeratotic rashes, keratolytic agents such as salicylic acid or urea cream should be combined with topical steroids and oral antihistamines. Fortunately, most rashes improve with supportive care and do not require modification or interruption of vemurafenib dose.

Vemurafenib The original drug has been launched in China and has entered the scope of medical insurance. The price of 240mg*56 tablets per box may be around 7,000 yuan, which is very expensive. The Turkish version of Vemurafenib Original drug listed overseas, specifications240mg*56 tablets, may cost more than 2,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively cheap. There is currently no generic version of Vemurafenib on the market. For more drug information and specific prices, please consult a medical consultant.